

Resource Summary Report

Generated by [NIF](#) on Sep 17, 2026

697

RRID:CVCL_0079

Type: Cell Line

Proper Citation

RRID:CVCL_0079

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0079

Proper Citation: RRID:CVCL_0079

Description: Cell line 697 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Childhood B acute lymphoblastic leukemia

Defining Citation: [PMID:6982733](#), [PMID:7630190](#), [PMID:7888679](#), [PMID:9108419](#), [PMID:9823951](#), [PMID:10490826](#), [PMID:11021758](#), [PMID:11843816](#), [PMID:15843827](#), [PMID:20164919](#), [PMID:20519628](#), [PMID:20575032](#), [PMID:21538216](#), [PMID:22460905](#), [PMID:25984343](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:29786757](#), [PMID:30285677](#), [PMID:30629668](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31160637](#), [PMID:31305009](#), [PMID:31978347](#), [PMID:35124168](#), [PMID:35354797](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: LL-100 blood cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: 697

Synonyms: Line 697, EU-3, Emory University-3

Cross References: BTO:BTO_0001969, CLO:CLO_0001008, EFO:EFO_0022690, CLDB:cl117, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ArrayExpress:E-MTAB-7721, ArrayExpress:E-MTAB-7722, BioGRID_ORCS_Cell_line:1757, BioSample:SAMN03473591,

BioSample:SAMN10988566, cancercellines:CVCL_0079, Cell_Model_Passport:SIDM01076, ChEMBL-Cells:ChEMBL3308147, ChEMBL-Targets:ChEMBL2366253, Cosmic:906800, Cosmic:1037742, Cosmic:1130252, Cosmic:1191693, Cosmic:1524788, Cosmic:2396142, Cosmic:2427693, Cosmic:2649230, Cosmic-CLP:906800, DepMap:ACH-000070, DSMZ:ACC-42, DSMZCellDive:ACC-42, EGA:EGAS00001000978, GDSC:906800, GEO:GSM236777, GEO:GSM236813, GEO:GSM886843, GEO:GSM887907, GEO:GSM1669562, GEO:GSM5137704, GEO:GSM5137749, IARC_TP53:21153, IZSLER:BS TCL 241, LiGeA:CCLE_726, LINCS_LDP:LCL-1042, Lonza:235, PharmacDB:697_26_2019, PRIDE:PXD023662, PRIDE:PXD030304, Progenetix:CVCL_0079, PubChem_Cell_line:CVCL_0079, Wikidata:Q54604500

ID: CVCL_0079

Record Creation Time: 20220427T215058+0000

Record Last Update: 20260913T011838+0000

Ratings and Alerts

No rating or validation information has been found for 697.

No alerts have been found for 697.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 13 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Garcia C, et al. (2026) FATP2-mediated lipid metabolism enhances chimeric antigen receptor T-cell therapy resistance in B-cell acute lymphoblastic leukemia. *Leukemia*, 40(8), 1763.

Ng HL, et al. (2026) BCR::ABL1-Induced Enhancer Reprogramming Uncovers Hypersensitivity of Ph+B-ALL Cells to Enhancer-Targeting Drugs. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 13(25), e17231.

Chen Z, et al. (2025) YTHDF2 promotes ATP synthesis and immune evasion in B cell malignancies. *Cell*, 188(2), 331.

Oles AR, et al. (2025) MyoD is essential in rhabdomyosarcoma by promoting survival through differentiation and CYLD. *iScience*, 28(8), 113149.

Chen HC, et al. (2024) Novel immunotherapeutics against LGR5 to target multiple cancer types. *EMBO molecular medicine*, 16(9), 2233.

Calbert ML, et al. (2024) 4'-Ethynyl-2'-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress. *Molecular cancer therapeutics*, 23(5), 683.

Kolekar P, et al. (2024) SJPedPanel: A Pan-Cancer Gene Panel for Childhood Malignancies to Enhance Cancer Monitoring and Early Detection. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(18), 4100.

Pillsbury CE, et al. (2023) Siglec-15 Promotes Evasion of Adaptive Immunity in B-cell Acute Lymphoblastic Leukemia. *Cancer research communications*, 3(7), 1248.

Barnett KR, et al. (2023) Epigenomic mapping reveals distinct B cell acute lymphoblastic leukemia chromatin architectures and regulators. *Cell genomics*, 3(12), 100442.

Pal D, et al. (2022) hiPSC-derived bone marrow milieu identifies a clinically actionable driver of niche-mediated treatment resistance in leukemia. *Cell reports. Medicine*, 3(8), 100717.

Sadras T, et al. (2021) Developmental partitioning of SYK and ZAP70 prevents autoimmunity and cancer. *Molecular cell*, 81(10), 2094.

Lu X, et al. (2019) MTA2/NuRD Regulates B Cell Development and Cooperates with OCA-B in Controlling the Pre-B to Immature B Cell Transition. *Cell reports*, 28(2), 472.

Jing D, et al. (2018) Lymphocyte-Specific Chromatin Accessibility Pre-determines Glucocorticoid Resistance in Acute Lymphoblastic Leukemia. *Cancer cell*, 34(6), 906.